ArticleFrontiers in pharmacology2026
Curcumin alleviates diabetic encephalopathy by attenuating cerebral microvascular ferroptosis: involvement of KEAP1/Nrf2 signalling.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cerebral microvascular injury and ferroptosis are increasingly implicated in diabetic encephalopathy (DE). This study investigated whether curcumin (Cur) alleviates DE by attenuating cerebral microvascular ferroptosis and examined the involvement of KEAP1/Nrf2-related signalling. Methods: Diabetic rats were treated with Cur for 8 weeks, with metformin as a positive control. Metabolic parameters, cognitive function, hippocampal histopathology, cerebral microvascular tight-junction proteins, oxidative stress, and ferroptosis-related markers were evaluated. Brain untargeted metabolomics and exploratory network analysis were integrated with molecular experiments to generate and experimentally evaluate mechanistic hypotheses. An HGHF-induced bEnd.3 cell model, together with erastin, ferrostatin-1, and ML385 interventions, was used for Results: Cur improved metabolic abnormalities, cognitive impairment, and hippocampal injury in diabetic rats. Untargeted metabolomics revealed ferroptosis-related metabolic alterations, including changes in glutathione-, taurine-, and polyunsaturated fatty acid-related metabolism. Cur reduced oxidative stress, restored tight-junction protein expression, and attenuated ferroptosis-related changes in cerebral microvessels. Experimental analyses further showed coordinated regulation of KEAP1, NRF2, HO-1, GCLC, GPX4, ACSL4, and NOX4 Conclusion: Cur alleviated DE-related metabolic, cognitive, and hippocampal abnormalities and attenuated ferroptosis-associated cerebral microvascular injury. KEAP1/Nrf2-related signalling contributed to these protective effects. These findings link Cur-mediated neuroprotection to the regulation of cerebral microvascular ferroptosis and support its further investigation in diabetes-associated cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.